Twist Bioscience Co. (NASDAQ:TWST) CEO Sells $98,265.82 in Stock

Twist Bioscience Co. (NASDAQ:TWST) CEO Emily M. Leproust sold 2,402 shares of the stock in a transaction dated Thursday, March 6th. The shares were sold at an average price of $40.91, for a total transaction of $98,265.82. Following the completion of the sale, the chief executive officer now directly owns 662,692 shares in the company, valued at approximately $27,110,729.72. The trade was a 0.36 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.

Twist Bioscience Price Performance

NASDAQ:TWST opened at $39.32 on Thursday. The firm has a market cap of $2.35 billion, a price-to-earnings ratio of -11.63 and a beta of 2.15. Twist Bioscience Co. has a 12-month low of $27.41 and a 12-month high of $60.90. The company has a current ratio of 4.96, a quick ratio of 4.62 and a debt-to-equity ratio of 0.03. The company’s 50-day moving average is $46.18 and its two-hundred day moving average is $45.39.

Twist Bioscience (NASDAQ:TWST) last announced its quarterly earnings data on Monday, February 3rd. The company reported ($0.53) earnings per share for the quarter, topping the consensus estimate of ($0.62) by $0.09. The business had revenue of $88.70 million for the quarter, compared to analyst estimates of $86.96 million. Twist Bioscience had a negative net margin of 59.76% and a negative return on equity of 32.69%. The company’s revenue was up 24.1% on a year-over-year basis. During the same period in the prior year, the firm posted ($0.75) EPS. Research analysts expect that Twist Bioscience Co. will post -2.12 EPS for the current year.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the stock. Massachusetts Financial Services Co. MA lifted its holdings in shares of Twist Bioscience by 215.9% during the 3rd quarter. Massachusetts Financial Services Co. MA now owns 29,314 shares of the company’s stock worth $1,324,000 after acquiring an additional 20,035 shares during the period. Barclays PLC raised its holdings in Twist Bioscience by 214.8% in the third quarter. Barclays PLC now owns 153,039 shares of the company’s stock valued at $6,913,000 after buying an additional 104,420 shares during the period. FMR LLC raised its holdings in Twist Bioscience by 6.0% in the third quarter. FMR LLC now owns 218,561 shares of the company’s stock valued at $9,875,000 after buying an additional 12,327 shares during the period. Avanza Fonder AB purchased a new position in Twist Bioscience in the fourth quarter valued at approximately $1,059,000. Finally, BNP Paribas Financial Markets raised its holdings in Twist Bioscience by 128.1% in the third quarter. BNP Paribas Financial Markets now owns 38,032 shares of the company’s stock valued at $1,718,000 after buying an additional 21,357 shares during the period.

Wall Street Analyst Weigh In

TWST has been the topic of a number of research reports. Scotiabank reissued an “outperform” rating on shares of Twist Bioscience in a research note on Tuesday, February 4th. Robert W. Baird increased their price objective on shares of Twist Bioscience from $48.00 to $54.00 and gave the company an “outperform” rating in a research note on Tuesday, February 4th. TD Cowen reissued a “buy” rating and issued a $58.00 price objective on shares of Twist Bioscience in a research note on Tuesday, November 26th. Barclays set a $58.00 price objective on shares of Twist Bioscience and gave the company an “overweight” rating in a research note on Monday, February 3rd. Finally, Wolfe Research initiated coverage on shares of Twist Bioscience in a report on Friday, December 13th. They issued an “outperform” rating and a $60.00 target price on the stock. One analyst has rated the stock with a sell rating, one has assigned a hold rating and eight have assigned a buy rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $54.40.

Twist Bioscience Company Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.